Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells. [PDF]
IntroductionAbiraterone acetate is a key therapeutic agent for castration-resistant prostate cancer (CRPC), but the cancer resistance limits its long-term efficacy.
Chen L +5 more
europepmc +2 more sources
The anticancer agent abiraterone suffers from an extensive positive food effect after oral intake of the prodrug abiraterone acetate (Zytiga). The underlying processes determining postprandial abiraterone absorption were investigated in this study.
Marlies Braeckmans +2 more
exaly +3 more sources
The present work deals with the preparation and in vitro evaluation of liposomal formulations of abiraterone acetate. In the present work, abiraterone acetate-loaded liposomal formulation was formulated by thin lipid film method.
Sudipta Das +2 more
exaly +3 more sources
Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report. [PDF]
Abiraterone acetate is a steroidal inhibitor of cytochrome P450 17A1 indicated in the treatment of metastatic prostate cancer. This report examines the case of a 66-year-old patient diagnosed with prostate adenocarcinoma that had metastasized to the ...
Akpokavie D +4 more
europepmc +2 more sources
Abiraterone acetate is a prodrug of abiraterone used in combination with prednisone as a standard therapeutic strategy for hormone-resistant prostate cancer (mCRPC).
Pengcheng Xu, Yan Shen, Qiyue Wang
exaly +3 more sources
Abiraterone acetate 1000 mg/day, combined with prednisone 5 mg PO twice daily, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Celestia Higano +2 more
exaly +2 more sources
Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids. [PDF]
This case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and
Mohamed AS +6 more
europepmc +2 more sources
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA. [PDF]
Aim: Head-to-head studies of survival outcomes associated with different androgen receptor pathway inhibitor (ARPI) treatments for metastatic castration (hormone)-sensitive prostate cancer have not been conducted.
Lowentritt B +9 more
europepmc +2 more sources
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer. [PDF]
Background Abiraterone is a 17α-hydroxylase/C17-20 lyase inhibitor used for the treatment of metastatic castration-resistant prostate cancer (CRPC). This multi-center, randomized, open-label, active-controlled phase II study compared the pharmacodynamics
Lu X +32 more
europepmc +2 more sources
Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study From Vietnam. [PDF]
Introduction The optimal choice between docetaxel and abiraterone in combination with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) remains uncertain due to the lack of direct randomized trials.
Nguyen H +4 more
europepmc +2 more sources

